contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  createdAt
  changedAt
  isPremium
  authors {
    __typename
    name
    pageUrl
    id
  }
  companies {
    name
    id
  }
  tags {
    name
    id
  }
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
      researchContentUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


intervacc-publishes-the-2025-annual-report

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

changedAt

Intervacc is an animal health group that develops vaccines for animals. The company develops and sells vaccines against animal diseases based on its own technology platform with fused recombinant proteins. Sales are currently carried out through its own organization in the Nordic region and through its partner Dechra Pharmaceuticals in the rest of Europe. The company's headquarters are located in Hägersten.

USA’s godkendelse afgør denne akties skæbne. Produktet er godt, men de lokale studier skal stadig udføres korrekt for at opnå godkendelsen. Der er rekrutteret yderligere ekspertise til både ledelsen og bestyrelsen; lad os se, hvordan de præsterer. Der går nok et par år endnu. Det bliver spændende at se, hvornår og med hvilken sandsynlighed markedet begynder at indregne fremtiden.

Denne akties kurs er steget en smule, er der noget bemærkelsesværdigt i dataene eller nyhederne? Stigningen begyndte efter videoen blev udgivet, findes årsagen mon dér? Mine egne svenskkundskaber rækker ikke til at vurdere det.

Hej, helt nyt interview med Intervaccs nye CEO, Carl-Johan Dalsgaard, om bl.a. situationen på det amerikanske marked, udfordringer, der skal overvindes, samt fremtidsudsigter.

Ja, dens tid kommer endnu. Produktet er meget effektivt, men behovet for det er lidt relativt. Adoption tager tid. Salget er dog langsomt stigende, men USA-tilladelser er nødv

Interessant at kommercialiseringsprojektet for vaccineproduktet fortsætter, med flere lande under distribution osv. Selskabets aktiekurs er i sig selv helt i bund, hvis ikke endda under kælderen.                   Inderes              Intervacc and Dechra extend distribution agreement for Intervacc's equine...    Intervacc AB (publ) announces today that the five-year distribution agreement signed in April 2021 with its partner Dechra Pharmaceuticals PLC has been extended by two years. The extension will...

Det er værd at bemærke, at kunden er konservativ. Produktet er rigtig godt, markedsføringsarbejdet skal blot gøres.  For den risikovillige er der gode muligheder for at købe aktien. Den mindre risikovillige afventer salgstilladelse i USA; derfra kan der stadig komme overraskelser og omkostninger.

Intervacc Q2: Nettoomsætning 1,9 mio. (SEK)  Driftsunderskud -18 mio.  Periodens nettoresultat -18 mio. Sagt på jævnt dansk: en total fiasko. Det internationale salg af vidundervaccinen er altså på latterlige 160 tusind euro, hvilket er på niveau med omsætningen i et eller andet lokalt autoværksted i Kajaani. Alligevel er virksomhedens markedsværdi stadig 26 mio. euro. Jeg forstår det ikke…

Intervacc

Intervacc AB (publ) announces that the company's 2025 Annual Report has been published today. The annual report (in Swedish) is attached and an English unaudited translation of the report is...

Intervacc AB (publ) announces that the company's 2025 Annual Report has been published today. The annual report (in Swedish) is attached and an English unaudited translation of the report is available for download on the company's website <a href="https://intervacc.se/en/investors/reports/">intervacc.com</a>.For more information please contact: &nbsp;Carl-Johan Dalsgaard, CEOPhone: +46 (0)8 120 10 600E-mail: carl-johan.dalsgaard@intervacc.se&nbsp;The information was submitted for publication, through the agency of the contact person set out above on April 14, 2026 at 08.30 CET.About Intervacc Intervacc AB is an animal health group that develops vaccines for animals. The company's vaccines and vaccine candidates are based on many years of research at the Karolinska Institute and the Swedish University of Agricultural Sciences. The Intervacc share (Nasdaq: IVACC) is listed on the Nasdaq First North Growth Market. For more information, see intervacc.se&nbsp;Contact information for Certified AdviserEminova Fondkommission ABE-mail: adviser@eminova.se, Phone: +46 (0)8 - 684 211 10<div></div>